Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Pacira BioSciences Inc
PCRX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$36.33
-0.05
-0.14%
Dern. MÀJ: Oct 21, 4:00 PM
$36.33
-0.05
-0.14%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Pacira BioSciences Financials
Pacira BioSciences (PCRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq Falls Over 300 Points as Oil Prices Surge: Investor Sentiment Weakens, Fear & Greed Index Remains in ‘Fear’ Zone
Markets stayed fearful as index fell to 38; Dow gained, S&P/Nasdaq slipped amid oil surge and Iran tensions. PepsiCo and Pacira shares rose.
Avi Kapoor
PRO
Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est
Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.
Benzinga Newsdesk
PRO
Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate
Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.65 by 12.31 percent. This is a 1.35 percent decrease over earnings of $0.74 per share from
Benzinga Newsdesk
PRO
Pacira BioSciences Affirms FY2026 Sales Guidance of $745.000M-$770.000M vs $759.317M Est
Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in millions)2026 Financial GuidanceAmountEXPAREL net product sales$600 to $620Total revenues$745 to $770Non-GAAP gross
Benzinga Newsdesk
PRO
Pacira BioSciences Q1 Adj. EPS $0.60 Beats $0.56 Estimate, Sales $177.376M Beat $173.325M Estimate
Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.56 by 7.14 percent. This is a 3.23 percent decrease over earnings of $0.62 per share from
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
